Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Herpes Zoster Virus (HZV) Infections among Multiple Sclerosis Patients Treated with Various Disease Modifying Therapies
Multiple Sclerosis
P5 - Poster Session 5 (8:00 AM-9:00 AM)
9-023
To stratify the frequency of HZV infections by disease modifying therapy (DMT), age, and gender in multiple sclerosis (MS) patients.
DMTs may increase the risk for opportunistic infections, including herpes zoster. The relative frequency of HZV infection in this population is unknown. Furthermore, the relative distribution of cases per age group and gender is unreported.
We queried the Food and Drug Administration Adverse Event Reporting System (FAERS) for adverse events (“herpes zoster” and “varicella”) reported in MS patients between January 1999 and June 2019 receiving interferon beta (IFB), glatiramer acetate (GA), natalizumab (NAT), fingolimod (FIN), teriflunomide (TER), dimethyl fumarate (DMF), alemtuzumab (ALE), and ocrelizumab (OCR). We excluded reports where the “suspect drug” included two or more DMTs. We stratified the reports for each DMT, by year of report, age and gender.
3352 reports met our inclusion criteria. Annual report rates [mean (SD)] were highest for patients treated with NAT 81.9(91.9), and lowest for GA 2.1(2.5). Other DMTs: FIN 70.3(27.3); DMF 66(21); OCR 55.3(27.8); ALE 22.8(15); INF 22.6(18); TER 10.4(4.7). Reports were 4.7x more in females (ranging from 2.3x for ALE to 8.2x for IFB). The highest percentage of reports was in the sixth decade of life for all DMTs except ALE (fourth decade). Several reports were in individuals younger than 40 (25.0%).
HZV infections are variable based on DMT used, age, and gender. HZV reports were nearly 5x more frequent in females than males, and incidence among patients younger than 40 was higher than expected. Database limitations precluded calculations of incidence. We encourage further research into incidence and risk mitigation strategies of HZV in MS patients on DMTs.
Authors/Disclosures
Nicola Carlisle, MD (The Everett Clinic)
PRESENTER 		No disclosure on file
Sam Hooshmand, DO (Medical College of Wisconsin) Dr. Hooshmand has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genetech USA. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics . Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genetech USA. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Hooshmand has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for TG Therapeutics . Dr. Hooshmand has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen . The institution of Dr. Hooshmand has received research support from Novartis .
Michelle Maynard, PharmD (Froedtert Neurosciences Clinic) Dr. Maynard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Maynard has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Maynard has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono.
No disclosure on file
Ahmed Z. Obeidat, MD, PhD (Medical College of Wisconsin) Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Genentech. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for EMD Serono. Dr. Obeidat has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi/Genzyme . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon pharmaceuticals . Dr. Obeidat has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sandoz. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Obeidat has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for EMD Serono. Dr. Obeidat has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Banner life sciences . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi/genzyme. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Horizon therapeutics . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for TG Therapeutics . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AstraZeneca. The institution of Dr. Obeidat has received research support from NIH. The institution of Dr. Obeidat has received research support from NMSS and PCORI. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Expert opinion and key opinion leader with MJH life sciences . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Faculty Speaker with CMSC. Dr. Obeidat has a non-compensated relationship as a Board member with CMSC that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Obeidat has a non-compensated relationship as a Editorial Board Member with IJMSC that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Obeidat has a non-compensated relationship as a Reviewer Editor with Frontiers Neurology that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Obeidat has a non-compensated relationship as a Board of Trustee Member with National MS Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.